Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) saw a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 367 shares, a decrease of 86.9% from the May 31st total of 2,801 shares. Based on an average daily trading volume, of 4,811 shares, the days-to-cover ratio is presently 0.1 days.
Clinuvel Pharmaceuticals Trading Down 0.7%
CLVLY stock opened at $7.05 on Friday. The firm has a 50 day moving average of $6.72 and a 200-day moving average of $7.39. Clinuvel Pharmaceuticals has a 12-month low of $5.98 and a 12-month high of $9.00.
Clinuvel Pharmaceuticals Company Profile
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
Featured Articles
- Five stocks we like better than Clinuvel Pharmaceuticals
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
